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Summary.-This report gives the complete findings at one year of a study comparing
radiotherapy (Rt) with radiotherapy followed by 3-drug chemotherapy (RtC3) in
the treatment of histologically proven small-cell carcinoma of the lung of limited
extent.
Over the 12-month period there was a significantly increased survival for the
RtC3 patients (P-=0002) and at 12 months 180/ of the 121 Rt but 340% of the 115 RtC3
patients were alive (P=0-009). The median survival for the Rt series was 25 weeks and
for the RtC3 series 43 weeks.
There was evidence of recurrence of the primary cancer in 32 (32%) of the 99 Rt
and 20 (26°/,) of the 76 RtC3 patients who died. Distant metastases appeared earlier
and were more frequent in the Rt series (P<0-0001) and over the 12-month period
79%o of the Rt and570% of the RtC3 patients developed distant metastases (P<0*0005).
At 12 months only 8oo of the Rt but 26°, of the RtC3 patients were alive and free of
metastases.
Adverse reactions occurred much more frequently in the RtC3 series; 32% of the
Rt series as against 83°' of the RtC3 series had reactions, the most common being
nausea and vomiting (130, Rt, 710// RtC3) and the most serious being marrow de-
pression (23o% Rt, 54O/ RtC3).
No important differences were found among the survivors in the 2 series at 3, 6 or
12 months, in general condition, physical activity or respiratory function.
It is concluded that radiotherapy plus chemotherapy was superior to radiotherapy
alone, although chemotherapy did not protect patients from recurrence of primary
growth.
THE RESULTS of treatment of small-cell
carcinoma of the lung are poor, with an
overall 5-year survival of less than 1%.
Recent reports (Broder et al., 1977; Bunn
et al., 1977) extensively review the litera-
ture. Failure to cure is largely related to
the early appearance and thefrequency
of metastases. Current therapeutic trials
are almost all concerned with reducing
this frequency.
A previous MRC study, conducted
between 1962 and 1964, compared radio-
therapy with surgery in operable patients
with small-cell carcinoma. This showed a
slightly improved survival for the radio-
therapy series from 2 years (Medical
Research Council, 1966) maintained to
10 years (Fox & Scadding, 1973). However,
both were localized treatments, and not
directed at possible distant metastases.
When the present study was initiated
there was evidence from some studies
(Bergsagel et al., 1972; Hansen et al., 1972;
Eagan et al., 1973), but not from others
(Durrant et al., 1971; H0st, 1973), that
cytotoxic drugs, alone or in combination,
given in addition to radiotherapy, could
improve the survivalofpatientswithsmall-
cell carcinoma. The present study was
therefore undertaken to examine in a
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randomized multicentre trial whether, in
patients with "limited" disease (as defined
below), treatment with radiotherapy could
be improved by the addition of a course
of chemotherapy. This report gives the
results at one year for the full intake, and
rc-views them with respect to the results
of other recent studies.
PLAN ANI) CONDUCT OF THE STUD)Y
Eligibility.-Patients were eligible if they
had histologically or cytologically proven
small-cell carcinoma, and if their disease, on
clinical and radiographic evidence, was con-
fined to the mediastinum, the soft tissues of
one hemithorax, and the ipsilateral and con-
tralateral scalene and lower cervical nodes.
This "limited" disease could be encompassed
by a pair ofopposed radiation fields. Patients
with a pleural efftision occupying less than
one third of the thoracic cavity on the same
side as the tumour were included. Patients
were ineligible if they had received previous
treatment with radiotherapy, cytotoxic
chemotherapy or surgery (other than thorac-
otomy without resection), were over 70 years
of age, had a blood-urea concentration over
60 mg/100 ml (8-4 mM) or had serious con-
comitant disease contraindicating radio-
therapy or chemotherapy.
Histological diagnosis.-The diagnosis was
made by the pathologist from the referring
centre according to the WHO classification
(Kreyberg et al., 1967) on a specimen ob-
tained from bronchial, pleural, lung, medias-
tinal or cervical node biopsy, bronchial
brushings or sputum cytology. All the speci-
mens were later re-examined by a single
reference pathologist for confirmation of the
cell type.
Pretreatment investigations.-The pretreat-
ment investigations included a postero-
anterior chest radiograph, measurement of
the haemoglobin and blood-urea concentra-
tions, total white cell and platelet counts, and
liver-function tests (serum concentration of
bilirubin, alkaline phosphatase and alanine
transaminase or equivalent enzyme).
Marrow examination and radioactive iso-
tope scans for metastases were carried out
routinely in only a few centres. The decision
to admit a patient was not influenced by
these findings.
Treatment.-Patients were randomly allo-
cated to treatment with either:
1. Radiotherapy only (Rt), or
2. Radiotherapy followed by3-drugchemo-
therapy (RtC3).
Radiotherapy consisted of a supervoltage
midline dosage of 3000 rad in 15 fractions
over a period of 3 weeks, or a suitable bio-
logical equivalent (see Appendix).
Chemotherapy consisted of alternating
3-drug and 2-drug pulses at 3-week intervals
for a total of 10 pulses. Cyclophosphamide
500 mg/mi2 plus methotrexate 50 mg/mi2
were given by i.v. injection at 3-week inter-
vals for 10 pulses, 10 mg of metoclopramide
being included in the injection as an anti-
emetic. CCNU (1 - (2 - chloroethyl) - 3- cyclo-
hexyl-1-nitrosourea) 50 mg/mi2 was given
orally on the first and alternating pulses
thereafter, i.e. every 6 weeks for 5 pulses.
Initially chemotherapy was started as soon
as possible after the end of the course of
radiotherapy, but because of some episodes
of severe toxicity the protocol was changed
after the first 86 (46 Rt. 40 RtC3) patients
had been entered. An interval of 3 weeks was
introduced between the end of radiotherapy
and the first pulse. The chemotherapy could
be stopped before the completion of 10 pulses
or prolonged beyond 10 pulses if the patient's
progress warranted it.
Assessment of progress.-A report on each
patient was completed at 3-week intervals
for 30 weeks from the end of radiotherapy,
and monthly thereafter. It included informa-
tion on clinical assessments, evidence of
metastases and intercurrent infection, palli-
ative treatment, and any adverse reactions,
including those to palliative treatment. The
haemoglobin concentration and total white
cell and platelet counts wvere measured, and
chemotherapy was given, modified, or with-
held as indicated by the results, or other
toxicity.
RESULTS
Population in the study
Between March 1975 and April 1977,
253 (125 Rt, 128 RtC3) patients were
admitted from 16 centres within the UK.
Of these patients, 17 (4 Rt, 13 RtC3)
were excluded; in 11 the histology was not
small-cell; 1 was incorrectly classified as
having "limited" disease; I had inter-
current disease, and 4 were above the ageRADIOTHERAPY AND CHEMOTHERAPY FOR SMALL-CELL LUNG CANCER
TABLE 1. Pretreatment factors for all 236
patients in both series*
Factor
Sex:
M
F
Age (years):
<45
45-54
55-64
65--70
Clinical con(lition:
Good
Fair
PooI
Activity:
Gra(le 1-
2--
3-
4-
5-
-At work or active
retirement
-Full activity but
not at work
-Out and about but
activity restricted
-Confined to home/
hospital
-Bedridden
Respiratory assessment:
Grade 1 Climbs hills ani(t
stairs without
(lyspnoea
2 Walks any distance
on flat without
(lyspnoea
3 Walks over 100
yards at ownI speed
without dyspnoea
4 -Dyspnoea on
walking 100 yards
or less
5 Dyspnoea on mild
exertion, e.g.
undressing
* Information was not available o0
dition in 5, on activity in 6 an(d c
assessment in 6.
limit. There remain 236 (121 Rt
patients for analysis.
Condition on admission
The distributions ofsex, age and cliinical
status were similar in the two series (data
not presented here) and the amalgamated
findings are shown in Table I. The majority
(72%) of patients were male, 66% were
aged between 55 and 70, 58% were con-
sidered by their physician to be in "good"
clinical condition, 510% were in Activity
GCrades 1 or 2, that is, capable ofnormal or
Patients
No. 0
170 72
66 28
21 9
60 25
113 48
42 18
133 58
86 37
12 5
47 20
nearly normal activity, and therespiratory
assessment was normal or nearly normal
(Grades 1 or 2) in 50%.
Only 2 (1 Rt, 1 RtC3) patients had a
haemoglobin concentration below 9 0 g/dl.
(Of these, 1 (RtC3) had a haemoglobin
concentration of 6A4 g/dl with a blood film
suggestive of autoimmune haemolytic
anaemia; he was given a blood trans-
fusion before the start of radiotherapy,
but his anaemia rapidly became worse and
he died after only 3 doses ofradiotherapy.)
Marrow from the iliac crest was exam-
ined in 35 (15 Rt, 20 RtC3) patients and
malignant cells were found in 2 (1 Rt,
1 RtC3).
71 31 Interval between allocation and treatmient
74 32 Radiotherapy was started within a
36 16 week of allocation in 72% of the Rt and
2 1 80% of the RtC3 patients; in 15% and
110% respectively the interval was between
1 and 2 weeks, and in 120o and 90o
45 20 respectively more than 2 weeks.
71 31 Survival
The follow-up is complete for all the
56 24 patients at 52 weeks and the survival
curves for the 2 series (Fig. 1) showed no
difference over the first 3 months, i.e. well 43 19 a.fter the end of the course of radiothe-
rapy. Over the whole year, however, there
15 7 was a significantly increased survival for
n clinical con- the RtC3 series (P=0.002, log-rank test). rn respiratory At 52 weeks, 22 (18%) of the 121 Rt, but
39 (340o) of the 115 RtC3 patients were
alive (P-0.009). The median survival
115 RtC3) for the Rt patients was 25 weeks and for
the RtC3 patients 43 weeks.
Elvidence of primary growth at death
Of the 175 patients who died, only 29
(15 Rt, 14 RtC3) had a necropsy examina-
tion, and evidence of the primary growth
was present in 19, namely in 11 Rt and
8 RtC3 patients, but no residual growth
was found in 10 (4 Rt, 6 RtC3). Of the
11 Rt and 8 RtC3 patients with recurrence
of the primary growth, 9 and 5 respec-
tively also had distant metastases. In
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13 26 39 52
Weeks after allocation
FIG. 1. Survival from allocation (121 Rt and 115 RtC3 patients). Median survival: Rt, 25 weeks; RtC3,
43 weeks
TABLE II.-Cumulative occurrence and site of distant metastases
Distant metastases
Regimen
Rt
RtC3
Patients
assessed
121
115
Alive
at 12
months
22
39
All*
sites
No. %
96 79
66 57
Brain
No. %
28 23
27 23
Bone
No. %
37 31
23 20
Liver
No. %
59 49
46 40
Lymph
nodes
No. %
18 15
12 10
Opposite
lung
No. %
14 12
12 10
Other
No. 0/
16 13
14 12
* P=0 0005.
addition, a further 33 (21 Rt, 12 RtC3)
were reported to have died with clinical
or radiological evidence of persistence,
extension, or recurrence of the primary
growth.
Metastases
Table II shows the incidence of meta-
stases over the 12-month period; 79%
of the 121 Rt and 57% of the 115 RtC3
patients developed clinical evidence of
distant metastases (P=0.0005). However,
the differences between the series for
individual sites were small. At 12 months,
10 (8%) of the Rt and 30 (26%) of the
RtC3 patients were alive and considered
to be free of metastases. Fig. 2 illustrates
the percentages of Rt and RtC3 patients
with distant metastases, showing the
earlier and more frequent appearance of
secondary deposits in the Rt series (P<
0.0001).
Additionalpalliative treatment
Of the Rt series (Table III) 51% were
given additional palliative therapy, com-
pared with only 19% of the RtC3 series.
In the Rt series this was chemotherapy
alone in 15%, radiotherapy alone in 21%,
and both in 15%, and in the RtC3 series
it was radiotherapy alone in all cases.
Additional irradiation of the primary site
was undertaken in 5 Rt and 7 RtC3
patients, i.e. 5% of the 226 patients who
completed the prescribed course of radio-
therapy.
Adverse reactions
Adverse reactions (Table IV) were
much more frequent in the RtC3 series,
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FIG. 2.-Cumulative percentagre of patients with evidence of distant metastases
occurring in 32% of the 118 Rt and 83%
of the 112 RtC3 patients who started
treatment. A high proportion of episodes
in the Rt series were due to palliative
chemotherapy given after the primary
treatment. Although anti-emetics were
given as a routine, nausea and vomiting
were the most common reactions occurr-
ing, usually shortly after a pulse ofchemo-
therapy, in 13% of the Rt patients and
71% of the RtC3 patients.
Mouthulcers, sometimeswithdysphagia,
occurred in 3% of the Rt and in 26% of
the RtC3 patients, all ofthe former having
current chemotherapy, which included
methotrexate, for recurrence.
Depression of marrow function was the
most serious adverse reaction and occurred
in 23% of the Rt and 54% of the RtC3
patients. During the early months of the
study, when chemotherapy was started as
soon as the course of radiotherapy had
been completed, 4 RtC3 patients died from
acute marrow depression, all after the
first pulse of chemotherapy. Once an
interval of 3 weeks between the end of
radiotherapy and the start of chemo-
therapy had been introduced, there were
no further deaths attributable to toxicity,
although 2 Rt patients (1 of whom also
had palliative chemotherapy) and 4 more
RtC3 patients had transient pancytopenia.
The most common haematological reaction
in the Rt series was thrombocytopenia
(defined as a platelet count below 100 x
109/1), in 14% of the patients, and in the
RtC3 series was leucopenia (defined as a
white-cell count below 3 x 109/1), in 38%.
Modifications to chemotherapy in the RtC3
series
There were 101 patients in the RtC3
series who started their prescribed chemo-
therapy. Of these, 33 (33%) had no modi-
fication to their chemotherapy, 19complet-
ing the prescribed course (2 had in error
only 9 pulses) and 14 dying during the
course. There were 30 (30%) patients in
whom, on account of adverse reactions,
one or more doses were omitted, delayed
or modified, although 19 of the 30 even-
tually completed the course. Finally,
therapy was stopped prematurely in the
remaining 38 (38%) patients, in 22 on
account ofadverse reactions, in 15 because
the disease had progressed to such an
extent that the physician in charge con-
sidered it unwarranted to continue the
course, and in 1 because of default.
Nineteen patients had more than 10
pulses and 12 were still receiving chemo-
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TABLE III.-Additional palliative therapy
Regimen
Rt RtC3
Palliative therapy
Patients who completed
prescribed course of
radiotherapy
Total receiving palliative
therapy
Chemotherapy alone
Radiotherapy alone
Radiotherapy and
chemotherapy
Total receiving
radiotherapy
Sites irradiated:
Primary
Brain
Bones
Extrathoracie nodes
Other
therapy at one year
responding.
No. 0 No. %
11.7 100 109 100
60
17
25
51
15
21
21
0
21
19
0
19
18 15 0 0
43 37 21 19
5
5
18
16
4
7
7
10
2
3
because they were
TABLE V. Clinical condition at 12 months*
Factor Rt RtC3
General condition:
Good 8 17
Fair 5 12
Poor 5 3
Activity:
Gradet I & 2 7 13
3 8 14
2
4
Respiratory assessIenIit:
Gradiet I & 2 9 14
3 6 12
4 0 3
5 3 3
Numbers assesse(I 18 32
* Assessment, not available foi 4 Rt andl 7 RtC3
patients.
t Definiedl in Table 1.
felt unwell, with nausea, vomiting and
sometimes other manifestationsoftoxicity,
there were no overall differences in the 3
factors at any assessment in the 12 months.
Quality oflife
At 12 months (Table V) there were no
important differences between the dis-
tributions of the general condition, the
grade of physical activity or the grade
of the respiratory assessment for the 2
series, although the number of survivors
was small. The distributions based on the
larger numbers at 3 and at 6 months (not
tabulated here) were also similar for the 2
series. Although immediately after the
pulse ofchemotherapy some RtC3 patients
DISCUSSION
The present study desigin was based on
the results ofthe first MRC small-cell study
(Fox & Scadding, 1973) and it compares
the results of the better treatment from
that study, radiotherapy alone, with those
ofthe same treatment in combination with
chemotherapy. Two points are worthy of
note. First, the staging criteria for entry
were not as exclusive as in the first study,
for which only patients with clinically
TABLE IV. All adverse reactions reported in the 118 Rt and 112 RtC3
patients who started treatment
Regimen
_-
Type of
a(lverse reaction
Any
Nausea and/or vomiting
Mouth ulcers
Haematological
Haemoglobin <9 g/dl
White cells <3x 109/1
Platelets < I00x 109/1
Rash
Other
Death attributeed to toxicity
Rt RtC3
A ( -A ~
No. 0 No. O/
38 .32 93 83
15 13 79 71
4 3 29 26
27 23 60 54
10
10
17
0
0
0
0
8
8
14
22
42
26
8
16
0 0 4
20
38
23
7
14
4
6
J)
0() 0001
<-0.0001
<000001
<0 0001
0 02
-<-0-0001
N.S.
0 006
<0-0001
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resectable tumours were eligible. Secondly,
the first study did not define the radiation
dose as clearly as the present study.
In this study of 236 patients with small-
cell carcinoma of the lung of "limited"
extent, treatment with radiotherapy plus
chemotherapy (RtC3) proved to be
superior to treatment with radiotherapy
alone (Rt). Over the 12-month period
there was an increased survival as shown
by the survival curves; the median
survival was 43 weeks compared with
25 weeks, and at 12 months 3400 of
the patients compared with 1800 were
alive. In the RtC3 series 26% of the
patients were alive and free from overt
metastases at 12 months, but in the Rt
series only 8%. Furthermore, metastases
appeared earlier as well as more frequently
in the Rt series, 7900 of the patients com-
pared with 570o of RtC3 patients having
developed metastases by 12 months. All
these differences are statistically sig-
nificant. Over 5000 of the patients in the
Rt series received additional palliative
therapy compared with only 19% in the
RtC3 series, so that in practice the radio-
therapy frequently had tobesupplemented
by additional radiotherapy or by chemo-
therapy.
Although the advantages from the addi-
tion of the adjuvant chemotherapy are
clear-cut, they are somewhat disappoint-
ing in degree. Also the duration of follow-
up is not yet long enough to show whether
any worthwhile influence on long-term
survival will be achieved. Failure tocontrol
the disease in the majority of patients
may be ascribed to inadequate treatment
of the primary disease and inability of the
3-drug regimen to control metastatic
disease, particularly in the brain. In a sub-
stantial proportion of the patients neither
therapy was adequate to eliminate the pri-
mary growth. Thus, ofthe 29 patients who
had necropsy examinations among the 175
who died in the year, 11 of the 15 in the
Rt series and 8 of the 14 in the RtC3 series
had evidence of the primary growth at
postmortem examination; thus there was
no difference between the 2series. Afurther
21 and 12, respectively, were reported to
have died without necropsy with clinical or
radiological evidence ofpersistence, exten-
sion or recurrence of the primary growth;
again showing no difference between the
2 series. Altogether, 3000 of the patients
who died had evidence offailure to control
the primary growth. Although it might be
expected that higher doses of radiation
would have a greater effect on the primary
growth, Deeley (1966) found that the
consequent radiation damage to the lungs
reduced survival. It is not clear, therefore,
whether results would have been improved
by the choice of a higher radiation dose.
In this respect it is relevant that recur-
rence at the primary site rarely seemed to
be a major clinical problem since, of the
15 Rt and 14 RtC3 patients examined by
necropsy, all but 2 and 3, respectively, had
secondary deposits as well.
The choice of drugs was based on the
report (Hansen et al., 1976) that this 3-
drug combination containing CCNU ap-
peared superior to the regimen containing
only cyclophosphamide and methotrexate.
A modification of the regimen was intro-
duced in which the methotrexate wasgiven
as single i.v. doses of 50 mg/M2 once every
3 weeks instead ofas the smaller and more
frequent oral doses used by Hansen et al.
(1976). The i.v. route was used to ensure
patient compliance with the regimen and
the dose was selected after an initial
(unpublished) pilot study conducted by
the Working Party.
Although CCNU undoubtedly contribu-
ted considerably to the toxicity of the
regimen, it was felt important to include
it for the above reason, and also because
its lipid solubility permits good access
across the blood-brain barrier (Livingston,
1976). In the present study the drug regi-
men was not adequate to control meta-
stases, and the differences between the
two series in the frequency of metastases
in individual organs were very small. The
brain was equally involved in both series,
so that CCNU did not prevent cerebral
secondaries in this series, a disappointing
finding. A similar failure has been reported
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by Alexander et al. (1977), although in a
summary of collected data from the litera-
ture, Bunn et al. (1977), reported an inci-
dence of cerebral metastases of only 4-9%0
in patients after nitrosourea treatment
but 24.8% after other forms of chemo-
therapy.
Set against the gains for the chemo-
therapy series in the present study was the
much more frequent toxicity. This affected
83% of the patients, compared with less
than a third of the patients in the radio-
therapy series, even whenadversereactions
to all the palliative measures received by
both series are included. The most frequent
toxic effects in the chemotherapy series
were nausea and vomiting, which were
reported in 710% of the patients. Depres-
sion of marrow function occurred in 5400,
and not infrequently created problems of
management. Adverse reactions frequently
led to the abandonment of chemotherapy
or modification of the dosage schedule.
Even so, 38 ofall 101 patients who started
the allocated course of chemotherapy
completed the prescribed 10 pulses (some
withminormodifications) and, intheevent,
19 received extra pulses because they were
responding, and even at 12 months 12
were still receiving pulses. It is usual for
some degree of toxicity to be associated
with such chemotherapy regimens and the
present treatment was designed to be
acceptable for outpatient use. In general
this proved to be the case.
In diseases where long-term survival is
infrequent, the quality of life is particu-
larly important but difficult to measure
satisfactorily. Although the patients in the
chemotherapy series frequently reported
symptoms for hours after a pulse of
chemotherapy, the assessments of the
general condition, the degree of physical
activity and respiratory function by a
clinical grading showed no important
difference between the 2 series at any time
during the year. Of the survivors at one
year, a substantial proportion were in good
general condition, physically active and
without undue dyspnoea on exertion.
We are unable to make a detailed com-
parison of survival in our patients and
those from other series, as methods of
staging were dissimilar. However, the
median survival observed here is not as
good as for a few other series reported on
small numbers of patients. These are
around or slightly in excess of 12 months
(Broder et al., 1977). Cases in this present
series were designated "limited disease"
without taking into account the results
of isotope screening of liver and brain, or
of marrow examinations, even where
available. (Not all participating centres
were able to carry out these examinations
on all patients.) Some would undoubtedly
have been staged as "extensive" if these
procedures had been undertaken routinely.
Chemotherapy was begun 3 weeks after
the radiation treatment, thus entailing a
delay of around 6 weeks from the start of
the radiation to the start of cytotoxic
drugs. This delay may have had an adverse
effect on survival. We are currently inves-
tigating this possibility in the third MRC
small-cell study.
Finally, a word of caution about the
3-drug schedule used in this present in-
vestigation is necessary. Before the series
reported here, it had previously been
tested in a pilot study in 50 patients with
more extensive disease, and found to have
an acceptable level of toxicity. However,
in the new MRC study (Third MRC small-
cell study) this same radiotherapy plus
chemotherapy regimen has probably led
to some deaths associated with intractable
vomiting and dehydration. There have
also been deaths attributed to toxicity
after the first pulse of chemotherapy in
patients who were allocated the same
drugs in a regimen which differs only in
that the radiotherapy is preceded by 2
pulses of chemotherapy at intervals of 3
weeks. However, increasing the fluid intake
and giving the patient sodium bicarbonate
tablets for 48 h starting on the day ofeach
chemotherapy treatment appear to have
reduced or eliminated the risk.
In conclusion, this study has shown that
a 3-drug regimen of cyclophosphamide,
methotrexate and CCNU, given after a
8RADIOTHERAPY AND CHEMOTHERAPY FOR SMALL-CELL LUNG CANCER 9
relatively low dose of radiotherapy to the
primary lesion, has improved the survival
during 12 months' follow-up.
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Dr P. Ryan, Dr T. Skeoch, Dr H. I. Williams;
Yorkshire: Mr L. Campbell-Robson, Dr N. Chak-
rabarti, Mr J. S. Davidson, Dr W. Davidson, Dr
W. H. Helm, Prof. C. A. Joslin, Dr H. S. Kellett,
Dr A. J. King, Mr E. R. Lecutier, Dr D. Mackinnon,
Dr D. K. Stevenson, Dr J. Stone, Dr G. W. Storey,
Prof. R. L. Turner, Dr A. J. Ward.
Dr K. F. W. Hinson was the reference pathologist
for the study.
The trial was co-ordinated in the Medical Research
Council Tuberculosis and Chest Diseases UJnit by
Dr L. E. Hill assisted by Mr R. J. Stephens.
APPENDIX
TABLE.-Bioloqical equivalents
Overall Fractionation pattern (f=fraction)
time , A
in days 5f/week 3f/week 2f/week
11 10 f: 2650 rad 6 f: 2340 rad 4 f: 2160 rad
18 15 f: 3000 rad 9 f: 2655 rad 6 f: 2430 rad
25 20 f: 3460 rad 12 f: 3060 rad 8 f: 2800 rad
32 25 f: 3750 rad 15 f: 3330 rad 10 f: 3050 rad
Notes: 1. These doses were intended to be "tumour doses", i.e. mid-line
doses when parallel opposed fields are used.
2. These doses were considered to represent 80-85% of normal
tissue tolerance.
3. An allowance of 13% was made between 5 treatments per week
and 3 treatments per week.
4. An allowance of 23% was made between 5 treatments per week
and 2 treatments per week.
5. These doses were suitable for the volumes in the chest that are
usually treated when parallel opposed fields of 150 cm2 to
300 cm2 are applied.
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